William J. Kostis, Ph.D., M.D., from Harvard Medical School, and team set out to determine what impact statins might have on reducing cardiovascular event risk in male and female patients. They gathered and analyzed data on 18 clinical trials which had gender-specific outcomes. A total of 141,235 patients were involved in all the studies, of which 40,275 were female - there were a total of 21,468 cardiovascular events.
They found that those who were prescribed (randomly) statins had a considerably lower risk of a cardiovascular event compared to those on a placebo, usual care, or low-dose statin therapy. Females Odds Ratio were similar to men's - Odds Ratio: 0.81, 95% CI: 0.75 to 0.89; p < 0.0001, and Odds Ratio: 0.77, 95% CI: 0.71 to 0.83, p < 0.0001, respectively.
The authors explained that the benefits of statins, regardless of the baseline risk, or type of control, were similar for males and females. All cause mortality was also considerably lower for both the male and female patients who were on statin therapy.
In the same journal, the authors concluded in an Abstract:
"Statin therapy is associated with significant decreases in cardiovascular events and in all-cause mortality in women and men. Statin therapy should be used in appropriate patients without regard to sex." What are statins?
Statins, also known as HMG-CoA reductase inhibitors, belong to a class of medications that are commonly prescribed to reduce cholesterol levels. They can block the chemical action that occurs in the liver for making cholesterol.
Our bodies need cholesterol in order to function properly. However, very high levels can raise the risk of developing atherosclerosis -...